Succeeder(SH:688338)2025-02-27 07:50Financial Performance - Total revenue for 2024 reached ¥307,410,065.02, an increase of 11.59% compared to the previous year[4] - Net profit attributable to shareholders was ¥115,960,657.62, a decrease of 0.81% year-on-year[6] - The basic earnings per share remained unchanged at ¥1.10[4] - The weighted average return on net assets decreased by 0.45 percentage points to 7.09%[4] Assets and Equity - The company's total assets at the end of the reporting period were ¥1,752,579,058.40, reflecting a growth of 2.72% from the beginning of the period[6] - Shareholders' equity attributable to the parent company increased by 3.06% to ¥1,649,231,369.74[6] Revenue Growth Drivers - The growth in revenue was primarily driven by an increase in the number of coagulation product installations and users[6] Cost and Profitability Challenges - The decline in net profit was attributed to increased depreciation, operational, and relocation costs due to the commissioning of construction projects[6] Financial Data Integrity - No financial data or indicators showed a change of 30% or more during the reporting period[6] - The financial data presented is preliminary and subject to audit, with final figures to be disclosed in the annual report[7]